Compare Quest Diagnostics Inc (DGX) vs Genuine Parts Company (GPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Genuine Parts Company — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Genuine Parts Company trades at $122.5 (market cap $16.81B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Genuine Parts Company pays the higher dividend (3.48%). Which is the better fit depends on your goals.
| DGX | GPC | |
|---|---|---|
Market Cap | $22.80B | $16.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.02 | $149.26 |
52-Week Low | $166.42 | $92.47 |
Enterprise Value | $28.82B | $23.03B |
Dividend Yield | 1.67% | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
GPC trades at $123.52, down 1.67% over the past day, with technical indicators showing a bullish trend supported by moving averages. The company reported mixed quarterly earnings, missing estimates in Q3 and Q4 2025 but beating in Q1 2026, with Q2 2026 results expected on July 21, 2026. Revenue growth remains modest at $24.3B in 2025, though net income margins have compressed significantly to 0.24%. Analyst sentiment is mixed with a consensus price target of $133.00, representing a 7.7% upside from current levels.
GPC offers potential for moderate upside based on analyst targets and dividend stability, but faces headwinds from declining profitability margins and recent earnings misses. The stock's high P/E ratio of 280.73 suggests premium valuation despite weak earnings growth, while strong cash flow generation and Dividend King status provide some downside protection. Key risks include margin pressure and competitive threats in the automotive parts distribution sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
